EGFR and malignant pleural mesothelioma: The binding efficiency of 67Ga-Nimotuzumab in MRC-5 (cells with basal levels of EGFR), A431 (cells with EGFR-overexpression), and MSTO-211H (malignant pleural mesothelioma) cells was 6.9 ± 0.3%, 34.5 ± 1.9%, and 21.6 ± 1%, respectively.